165 related articles for article (PubMed ID: 23187773)
1. Updates in the treatment of multiple myeloma.
Berenson JR
Clin Adv Hematol Oncol; 2012 Oct; 10(10):667-9. PubMed ID: 23187773
[No Abstract] [Full Text] [Related]
2. The impact of response on bone-directed therapy in patients with multiple myeloma.
Larocca A; Child JA; Cook G; Jackson GH; Russell N; Szubert A; Gregory WM; Brioli A; Owen RG; Drayson MT; Wu P; Palumbo A; Boccadoro M; Davies FE; Morgan GJ
Blood; 2013 Oct; 122(17):2974-7. PubMed ID: 23974194
[TBL] [Abstract][Full Text] [Related]
3. Bone targeted therapy in breast cancer: present and future.
Huober J; Thürlimann B
Crit Rev Oncol Hematol; 2010 Apr; 74 Suppl 1():S7-10. PubMed ID: 20427030
[No Abstract] [Full Text] [Related]
4. Bone turnover markers as predictive tools for skeletal complications in men with metastatic prostate cancer treated with zoledronic acid.
Lein M; Miller K; Wirth M; Weissbach L; May C; Schmidt K; Haus U; Schrader M; Jung K
Prostate; 2009 May; 69(6):624-32. PubMed ID: 19143027
[TBL] [Abstract][Full Text] [Related]
5. Can bisphosphonates improve outcomes in patients with newly diagnosed multiple myeloma?
Morgan GJ
Crit Rev Oncol Hematol; 2011 Feb; 77 Suppl 1():S24-30. PubMed ID: 21353177
[TBL] [Abstract][Full Text] [Related]
6. The changing treatment paradigm in patients with newly diagnosed multiple myeloma: implications for nursing.
Tariman JD; Estrella SM
Oncol Nurs Forum; 2005 Nov; 32(6):E127-38. PubMed ID: 16270103
[TBL] [Abstract][Full Text] [Related]
7. Bisphosphonates in adjuvant treatment of early breast cancer.
; Harbeck N; von Minckwitz G; Thürlimann B
Crit Rev Oncol Hematol; 2010 Apr; 74 Suppl 1():S1. PubMed ID: 20427026
[No Abstract] [Full Text] [Related]
8. The use of thalidomide in myeloma therapy as an effective anticancer drug.
Sze DM; Brown R; Yang S; Ho PJ; Gibson J; Joshua D
Curr Cancer Drug Targets; 2006 Jun; 6(4):325-31. PubMed ID: 16848723
[TBL] [Abstract][Full Text] [Related]
9. Zoledronic acid: multiplicity of use across the cancer continuum.
Lipton A
Expert Rev Anticancer Ther; 2011 Jul; 11(7):999-1012. PubMed ID: 21806323
[TBL] [Abstract][Full Text] [Related]
10. Established role of bisphosphonate therapy for prevention of skeletal complications from myeloma bone disease.
Terpos E; Dimopoulos MA; Berenson J
Crit Rev Oncol Hematol; 2011 Feb; 77 Suppl 1():S13-23. PubMed ID: 21353176
[TBL] [Abstract][Full Text] [Related]
11. Zoledronic acid: a framework of emerging anticancer evidence throughout the cancer continuum.
Terpos E
Crit Rev Oncol Hematol; 2011 Feb; 77 Suppl 1():S1-2. PubMed ID: 21353175
[No Abstract] [Full Text] [Related]
12. Maintaining bone health in prostate cancer throughout the disease continuum.
Saad F; Eastham J
Semin Oncol; 2010 Jun; 37 Suppl 1():S30-7. PubMed ID: 20682370
[TBL] [Abstract][Full Text] [Related]
13. Is there a case for the early use of bisphosphonates in smouldering myeloma and MGUS? (Bisphosphonates in SMM & MGUS).
Sanders J; Crawford B; Gibson J; Joy Ho P; Iland H; Joshua D
Int J Lab Hematol; 2007 Oct; 29(5):395-7. PubMed ID: 17824924
[No Abstract] [Full Text] [Related]
14. Zoledronic acid to prevent skeletal complications in cancer: corroborating the evidence.
Smith MR
Cancer Treat Rev; 2005; 31 Suppl 3():19-25. PubMed ID: 16229955
[TBL] [Abstract][Full Text] [Related]
15. Bisphosphonates for Patients Diagnosed With Multiple Myeloma.
Mhaskar R; Djulbegovic B
JAMA; 2018 Oct; 320(14):1483-1484. PubMed ID: 30326511
[TBL] [Abstract][Full Text] [Related]
16. Three new drugs for multiple myeloma.
Med Lett Drugs Ther; 2016 May; 58(1495):e70-1. PubMed ID: 27192621
[No Abstract] [Full Text] [Related]
17. [Effects of zoledronic acid in the treatment of breast cancer].
Chen J; Liu ZY; Zhao LJ
Zhonghua Zhong Liu Za Zhi; 2011 Apr; 33(4):318-9. PubMed ID: 21575510
[No Abstract] [Full Text] [Related]
18. Design, synthesis, and biological evaluation of bone-targeted proteasome inhibitors for multiple myeloma.
Agyin JK; Santhamma B; Roy SS
Bioorg Med Chem Lett; 2013 Dec; 23(23):6455-8. PubMed ID: 24119559
[TBL] [Abstract][Full Text] [Related]
19. Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole.
Brufsky AM; Harker WG; Beck JT; Bosserman L; Vogel C; Seidler C; Jin L; Warsi G; Argonza-Aviles E; Hohneker J; Ericson SG; Perez EA
Cancer; 2012 Mar; 118(5):1192-201. PubMed ID: 21987386
[TBL] [Abstract][Full Text] [Related]
20. Prognostic variables for survival and skeletal complications in patients with multiple myeloma osteolytic bone disease.
Terpos E; Berenson J; Cook RJ; Lipton A; Coleman RE
Leukemia; 2010 May; 24(5):1043-9. PubMed ID: 20376081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
